ReviewCancer immunology, immunotherapy : CII2016
Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
Review in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 35 citations in OpenAlex.
- Multifunctional-engineered NK cells overcome tumor immunosuppression by combining PD-L1 and HLA-E targeting and endogenous IL15 production.Signal transduction and targeted therapy · 2026Article
- Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.Science advances · 2025Article
- Colorectal cancer-infiltrating NK cell landscape analysis unravels tissue-resident PD-1Frontiers in immunology · 2025Article
- Gamma-ray irradiation modulates PGRMC1 expression and the number of CD56+ and FoxP3+ cells in the tumor microenvironment of endometrial endometrioid adenocarcinoma.Radiation oncology journal · 2021Article
- Article
- Article
- Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.American journal of cancer research · 2021Review
- Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT.Frontiers in immunology · 2021Review
- Review
- Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor.Oncology letters · 2020Review
- Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?Cancers · 2020Review
- CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.International journal of molecular sciences · 2019Review
- Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.Cellular & molecular immunology · 2019Review
- An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.Frontiers in immunology · 2019Review
- Exploiting Human NK Cells in Tumor Therapy.Frontiers in immunology · 2019Review
- Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.Oncotarget · 2018Article
- Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.Journal of immunology research · 2018Article
- Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Protein & cell · 2017Review
- Thermal treatment of luteolin-7-O-β-glucoside improves its immunomodulatory and antioxidant potencies.Cell stress & chaperones · 2017Article
- NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well established that natural killer (NK) cells play an important role in the immunity against cancer, while the involvement of other recently identified, NK-related innate lymphoid cells is still poorly defined. In the haploidentical hematopoietic stem cell transplantation for the therapy of high-risk leukemias, NK cells have been shown to exert a key role in killing leukemic blasts residual after conditioning. While the clinical results in the cure of leukemias are excellent, the exploitation of NK cells in the therapy of solid tumors is still limited and unsatisfactory. In solid tumors, NK cell function may be inhibited via different mechanisms, occurring primarily at the tumor site. The cellular interactions in the tumor microenvironment involve tumor cells, stromal cells and resident or recruited leukocytes and may favor tumor evasion from the host's defenses. In this context, a number of cytokines, growth factors and enzymes synthesized by tumor cells, stromal cells, suppressive/regulatory myeloid and lymphoid cells may substantially impair the function of different tumor-reactive effector cells, including NK cells. The identification and characterization of such mechanisms may offer clues for the development of new immunotherapeutic strategies to restore effective anti-tumor responses. In order to harness NK cell-based immunotherapies, several approaches have been proposed, including reinforcement of NK cell cytotoxicity by means of specific cytokines, antibodies or drugs. These new tools may improve NK cell function and/or increase tumor susceptibility to NK-mediated killing. Hence, the integration of NK-based immunotherapies with conventional anti-tumor therapies may increase chances of successful cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.